Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19/CD22 CAR-T Cell Therapy as First-line Consolidation in Follicular Lymphoma
NCT07587840Phase 2Recruiting
- Sponsor
- Liping Dou
- Start
- Jan 2026
- Primary completion
- Jan 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of AUTO1/22 in follicular lymphoma (FL), sponsored by Liping Dou. Started Jan 2026; status: recruiting.
02
Drugs
AUTO1/22
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT07587840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07587840.